SCHEMBL17190815

SCHEMBL17190815

CCOCc1nc2c(N)nc3cc(/C=C/C(=O)OCC)ccc3c2n1CC(C)(C)OCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 19/20 1.00
TLR8 Q9NR97 15/20 1.00
NUDT1 P36639 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17973528 0.95 TLR7 (0.90) TLR7TLR8NUDT1
SCHEMBL17181401 0.92 TLR7 (0.86) TLR7TLR8NUDT1
SCHEMBL17181399 0.92 TLR7 (0.86) TLR7TLR8NUDT1
SCHEMBL21968102 0.85 TLR7 (0.75) TLR7TLR8NUDT1
SCHEMBL17190812 0.85 TLR7 (0.73) TLR7TLR8NUDT1
SCHEMBL17181435 0.84 TLR7 (1.00) TLR7TLR8NUDT1
SCHEMBL17190811 0.84 TLR7 (0.72) TLR7TLR8NUDT1
Hydrochloric Acid SCHEMBL17181392 0.83 TLR7 (0.98) TLR7TLR8NUDT1
SCHEMBL4530102 0.83 TLR7 (0.70) TLR7TLR8NUDT1
SCHEMBL17181371 0.81 TLR7 (1.00) TLR7TLR8NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3134402-B1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS HOFFMANN LA ROCHE (CH) 2020-05-06 EP claimed
US-20230310469-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS Accencio LLC 2023-10-05 US disclosed
US-20230310469-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS Accencio LLC 2023-10-05 US disclosed
EP-3134402-B1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS HOFFMANN LA ROCHE (CH) 2020-05-06 EP disclosed
US-9447097-B2 4-amino-imidazoquinoline compounds HOFFMANN-LA ROCHE INC. (US) 2016-09-20 US disclosed
US-9447097-B2 4-amino-imidazoquinoline compounds HOFFMANN-LA ROCHE INC. (US) 2016-09-20 US disclosed
US-9334268-B2 4-amino-imidazoquinoline compounds HOFFMAN-LA ROCHE INC. (US) 2016-05-10 US disclosed
US-9334268-B2 4-amino-imidazoquinoline compounds HOFFMAN-LA ROCHE INC. (US) 2016-05-10 US disclosed
WO-2015162075-A1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2015-10-29 WO disclosed
US-20150299194-A1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-10-22 US disclosed
US-20150299194-A1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310469-A1 METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS TLR3, TLR7, TLR8 TLR7 2/4885TLR8 3/4885NUDT1 2544/4885
US-20150299194-A1 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS TLR4, TLR1, TLR5 TLR7 4/4885TLR8 9/4885NUDT1 2019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.